Managing First-Line Metastatic Renal Cell Carcinoma: Favorable-Risk Disease

Elizabeth Pan; Danielle Urman; Carmel Malvar; Rana R McKay

doi:10.1016/j.hoc.2023.04.017

Managing First-Line Metastatic Renal Cell Carcinoma: Favorable-Risk Disease

Hematol Oncol Clin North Am. 2023 Oct;37(5):943-949. doi: 10.1016/j.hoc.2023.04.017. Epub 2023 May 29.

Authors

Elizabeth Pan¹, Danielle Urman¹, Carmel Malvar¹, Rana R McKay²

Affiliations

¹ University of California San Diego, Moores Cancer Center, 3855 Health Sciences Drive, #0987, La Jolla, CA 92093-0987, USA.
² University of California San Diego, Moores Cancer Center, 3855 Health Sciences Drive, #0987, La Jolla, CA 92093-0987, USA. Electronic address: [email protected].

PMID: 37258352
DOI: 10.1016/j.hoc.2023.04.017

Abstract

Defining metastatic renal-cell carcinoma as a favorable risk depends on clinical risk-stratification tools such as the International Metastatic Renal Cell Carcinoma Database Consortium or the Memorial Sloan-Kettering Cancer Center scores. The favorable-risk disease tends to have better prognosis and survival compared with disease stratified as either intermediate or poor risk and can be attributed in part to an indolent tumor biology. Several phase 3 clinical trials have demonstrated an improvement in progression-free survival and objective response rate, but not overall survival benefit with combinations of immunotherapy and vascular endothelial growth factor tyrosine kinase inhibitors compared with sunitinib in favorable-risk disease.

Keywords: Favorable-risk; Immunotherapy; Renal cell carcinoma; VEGF-TKI.

Publication types

Review

MeSH terms

Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / pathology
Humans
Kidney Neoplasms* / drug therapy
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Treatment Outcome
Vascular Endothelial Growth Factor A

Substances

Vascular Endothelial Growth Factor A
Protein Kinase Inhibitors